Drugs / 89Sr
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05740488 | Jan 2022 → Apr 2025 | prostate cancer, hereditary, 10 | Zhujiang Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Sr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05740488 ↗ |
| Route | Intravenous | “100\~150MBq(based on weight), iv, q90d” NCT05740488 ↗ |